Objective To investigate the clinical efficacy of three-dimensional conformal radiotherapy combined with XELOX program chemotherapy in the treatment of postoperative local recurrence of rectal cancer.Methods One hundred and twenty-nine patients with postoperative local recurrence of rectal cancer were divided by random digits table method into treatment group (65 cases) and control group (64 cases).The patients in treatment group were treated with three-dimensional confonmal radiotherapy combined with XELOX program chemotherapy.The patients in control group were treated with XELOX program chemotherapy.The short-term effect,symptom control rate,long-term efficacy and adverse reaction were observed.Results The efficiency rate in treatment group [ 90.8％ (59/65) ] was significantly higher than that in control group [ 73.4％(47/64) ] (P ＜ 0.05 ).The improvement rates of pain,hematochezia and incomplete obstruction between treatment group and control group had significantly statistical differences [95.2％(40/42) vs.75.0％(27/36),92.9％(26/28) vs.79.5％(31/39),94.7％(18/19) vs.75.0％(9/12)](P ＜0.05).The 1,2,3-year survival rates between treatment group and control group had significantly statistical differences [ 67.7％ ( 42/62 ) vs.43.5 ％ ( 27/62 ),53.2％ ( 33/62 ) vs.30.6％ ( 19/62 ),38.7％ ( 24/62 )vs.14.5％ (9/62)] (P ＜ 0.01 ).The adverse reaction in two groups were mainly bone marrow suppression,gastrointestinal reactions,hand-fcot syndrome and radiation cystitis.The incidence rate of adverse reaction in treatment group was slightly higher than that in control group,but there was no significant difference between two groups (P ＞ 0.05).Conclusion Three-dimensional conformal radiotherapy combined with XELOX program chemotherapy in patients with postoperative local recurrence of rectal cancer can improve the short-term effect,symptom control rate and long-term survival rate.

BACKGROUNDThere is no effective regimen for recurrent small cell lung cancer patients now. The aim of this study is to assess the activity and toxicity of topotecan combined with cisplatin in the treatment of recurrent small cell lung cancer patients.

METHODSTwenty-eight patients with progressive disease after one first-line regimen enrolled in the study from May 2002 to October 2004. Topotecan was given at the dose of 1.2mg/m² from 1st to 4th days and cisplatin was administered at the dose of 25mg/m² from 5th to 7th days in a cycle of 3 weeks. The patients could be evaluated at least after 2 cycles.

RESULTSOne patient got complete response and ten patients got partial response in this group. The overall response rate was 39.3% , and the response rate of refractory group and sensitive group was 37.5% (3/8) and 40.0% (8/20) respectively. The median time to progression was 4.2 months. The main toxicity was hematological toxicity. Grade III+IV neutropenia occurred in 42.9% (12/28) of the patients.

CONCLUSIONSThe regimen of topotecan and cisplatin shows better activity in retreated small cell lung cancer patients. The main toxicity is hematological toxicity and can be tolerated.